PharmaMar's Aplidin, or plitidepsin, taken in combination with dexamethasone was found by investigators to extend survival and time to disease progression or death in patients with relapsed or refractory multiple myeloma who have been heavily treated, compared with outcomes for those taking dexamethasone alone. Findings from the late-stage trial were published in the journal Annals of Hematology.
Study tests plitidepsin combo in patients with multiple myeloma
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.